Patent for Making Combination Chemotherapy Work Better

SAN JOSE, Calif., March 24 /PRNewswire/ -- Patent 7,507,704 issued on 03/24/09
to NexGen Biomedical, Inc. founder Mark Zamoyski of San Jose, California
discloses an improved method of treating lung, brain, pancreatic, breast and
colon cancers that are driven by a mutation known as HER1 overexpression (also
called EGFR or c-ErbB-1). The patent presents a case for why today's
concurrent HER1 blocker / S-Phase cytotoxic protocols achieve only a fraction
of the potential inherent in the combination of the underlying drugs. Novel
synergistic protocols are provided.

All proliferating cells progress through 4 distinct phases, in sequence, G1,
S, G2, and M. "S-Phase cytotoxics, such as Pfizer's irinotecan or Eli Lilly's
gemcitabine, are capable of killing virtually all cells that are in the
S-Phase, however, less than one third of cancer cells are typically in the
S-Phase during chemotherapy," explains Mark Zamoyski, the inventor.
"Mechanistically, HER1 blockers, such as Genentech's erlotinib, AstraZeneca's
gefitinib, ImClone's cetuximab and Amgen's panitumumab arrest and aggregate
HER1 overexpressing cancer cells in the G1-Phase. This results in S-Phase
depletion, greatly reducing the number of cancer cells killed by the S-Phase
cytotoxic." The patent provides a crucial modification to the protocols by
adding existing drugs to provide S-Phase enrichment at the appropriate time,
while using the HER1 blocker to inhibit tumor regrowth between administrations
of S-Phase cytotoxic.

Patent 7,507,704 is the third in a series of patents awarded to Mr. Zamoyski
for cancer specific S-Phase enrichment relative to administrations of S-Phase
cytotoxic chemotherapy. "With less than one third of cancer cells in the
S-Phase, today's cytotoxic protocols only extend life expectancy by a few
months. Doubling the number of cancer cells in the S-Phase would provide a
way of indefinitely keeping most cancers in check. Tripling the number, while
simultaneously preventing tumor regrowth between administrations of S-Phase
cytotoxic, is required under established principles of chemotherapy for
curative outcome. Drugs capable of doing both already exist for many cancers,
providing the potential for an immediate advance in cancer treatment under our
protocols," according to Mr. Zamoyski. Richard Lepidi, NexGen's business
advisor, concludes "The IP has now reached a critical mass that allows us to
pursue business collaborations for clinical development of the technology."

More information is available at www.nexgen.biz under Cell Cycle Synchronous
Chemotherapy.

SOURCE NexGen Biomedical, Inc.

Mark Zamoyski, NexGen Biomedical, Inc., +1-408-365-1170, mark@nexgen.biz